Finally, there was a trend toward lower likelihood of adverse clinical endpoints with neurohormonal therapy compared with placebo, but this did not reach statistical significance (risk ratio 0.80; 95% CI: 0.53 to 1.20; I 2 = 71%).
← all excerpts
Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients with Cancer Undergoing Chemotherapy.
1
—
—